Published in Am J Respir Crit Care Med on February 08, 2007
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med (2009) 2.20
Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis (2009) 1.78
The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One (2010) 1.46
Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis (2011) 1.38
Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res (2011) 1.30
Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South India. PLoS One (2011) 1.27
Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC Infect Dis (2013) 1.26
Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol (2010) 1.25
Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis (2011) 1.20
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med (2009) 1.14
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med (2011) 1.13
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis (2011) 1.11
Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis (2010) 1.05
When tuberculosis comes back: who develops recurrent tuberculosis in california? PLoS One (2011) 1.05
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother (2012) 1.04
Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int J Tuberc Lung Dis (2011) 1.01
HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. AIDS Patient Care STDS (2009) 1.01
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India. Indian J Med Res (2011) 0.94
Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One (2012) 0.93
Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med (2010) 0.90
HIV status determination among tuberculosis patients from California during 2008. J Public Health Manag Pract (2013) 0.90
Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis (2010) 0.90
Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis (2010) 0.87
Respiratory infection complicating HIV infection. Curr Opin Infect Dis (2008) 0.86
Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment. Clin Chest Med (2013) 0.84
Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. PLoS One (2013) 0.83
Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tuberc Lung Dis (2013) 0.83
Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res (2011) 0.83
HIV testing of tuberculosis patients by public and private providers in New York City. J Community Health (2014) 0.82
Impact of HIV Status on Treatment Outcome of Tuberculosis Patients Registered at Arsi Negele Health Center, Southern Ethiopia: A Six Year Retrospective Study. PLoS One (2016) 0.82
Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004. BMC Public Health (2010) 0.81
Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study. BMC Infect Dis (2013) 0.79
Treatment of tuberculosis in HIV-infected patients: we need to know more. Am J Respir Crit Care Med (2007) 0.77
Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther (2016) 0.75
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother (2016) 0.75
Enhancing the impact of antiretroviral scale-up on the HIV-associated tuberculosis epidemic in Malawi. Public Health Action (2014) 0.75
5-Arylaminouracil Derivatives as Potential Dual-Action Agents. Acta Naturae (2015) 0.75
On treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med (2008) 0.75
Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008. Public Health Rep (2014) 0.75
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol (1993) 45.22
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med (1999) 8.80
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS (2002) 5.67
International standards for tuberculosis care. Lancet Infect Dis (2006) 4.67
Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 4.45
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med (1998) 3.64
Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis (2004) 3.40
A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med (2004) 3.24
Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med (1995) 3.09
Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J Clin Microbiol (1996) 2.91
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (1999) 2.62
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet (1995) 2.42
Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis (2002) 2.30
Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR Morb Mortal Wkly Rep (1987) 2.05
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS (2000) 1.82
[Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. Bull Int Union Tuberc (1978) 1.75
Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. Center for Disease Control and Prevention. MMWR Recomm Rep (1993) 1.71
Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis (2005) 1.63
Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med (1996) 1.48
A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis (2001) 1.46
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS (1995) 1.46
Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis (2001) 1.43
Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis (1996) 1.40
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis (2004) 1.36
Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS (2003) 1.29
Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med (2004) 1.09
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS (1999) 1.05
Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS. Clin Infect Dis (1994) 0.92
Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Eur Respir J (2005) 0.91
Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients. Int J Tuberc Lung Dis (2005) 0.87
A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med (1994) 0.85
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 9.35
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 8.90
Clinical practice. Latent tuberculosis infection. N Engl J Med (2002) 5.64
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med (2002) 5.42
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 4.63
Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med (2002) 4.14
Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis (2008) 4.14
Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis (2011) 3.62
Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis (2003) 3.27
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med (2010) 3.18
Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol (2013) 2.89
Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis (2006) 2.87
Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.80
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med (2004) 2.75
Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med (2007) 2.71
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis (2010) 2.61
Slum health: diseases of neglected populations. BMC Int Health Hum Rights (2007) 2.59
Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis (2011) 2.59
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med (2007) 2.36
Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis (2007) 2.33
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med (2014) 2.29
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis (2009) 2.25
Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med (2003) 2.15
Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med (2011) 2.14
Evaluation of the Center for Disease Control and Prevention's HIV behavioral surveillance of men who have sex with men: sampling issues. Sex Transm Dis (2005) 2.10
Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis (2012) 2.00
Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med (2010) 1.95
Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr (2011) 1.95
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc (2006) 1.94
Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis (2009) 1.92
Knowledge of sexual partner's HIV serostatus and serosorting practices in a California population-based sample of men who have sex with men. AIDS (2006) 1.88
Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol (2008) 1.80
Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One (2008) 1.79
Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis (2008) 1.74
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2015) 1.68
Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis (2005) 1.63
HIV prevalence and sexual risk behaviors among men who have sex with men: results from a statewide population-based survey in California. J Acquir Immune Defic Syndr (2006) 1.61
The impact of Medicaid managed care on hospitalizations for ambulatory care sensitive conditions. Health Serv Res (2005) 1.55
Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest (2005) 1.49
Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis (2002) 1.49
Pulmonary specialty training to improve respiratory health in low- and middle-income countries. Needs and challenges. Ann Am Thorac Soc (2015) 1.47
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis (2004) 1.46
Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS One (2007) 1.45
Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One (2010) 1.45
Global scale-up of the programmatic management of multidrug-resistant tuberculosis. Indian J Tuberc (2014) 1.43
Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med (2012) 1.41
Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother (2005) 1.40
Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis (2011) 1.38
A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax (2007) 1.35
Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States. MMWR Morb Mortal Wkly Rep (2016) 1.27
Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2006) 1.24
Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol (2012) 1.24
Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. Am J Respir Crit Care Med (2011) 1.24
Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS (2002) 1.20
The genome of Mycobacterium africanum West African 2 reveals a lineage-specific locus and genome erosion common to the M. tuberculosis complex. PLoS Negl Trop Dis (2012) 1.20
Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One (2013) 1.19
Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med (2010) 1.18
International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control. Expert Rev Anti Infect Ther (2007) 1.18
A molecular epidemiological assessment of extrapulmonary tuberculosis in San Francisco. Clin Infect Dis (2003) 1.15
Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med (2008) 1.15
Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One (2010) 1.15
The effect of venue sampling on estimates of HIV prevalence and sexual risk behaviors in men who have sex with men. Sex Transm Dis (2006) 1.15
Mycobacterium africanum: a new opportunistic pathogen in HIV infection? AIDS (2005) 1.13
IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol (2007) 1.13
Early detection of tuberculosis outbreaks among the San Francisco homeless: trade-offs between spatial resolution and temporal scale. PLoS One (2007) 1.13
Use of saliva as a lubricant in anal sexual practices among homosexual men. J Acquir Immune Defic Syndr (2009) 1.13